Bio2’s patented Cross-Linked Microstructure process bonds bioactive glass fiber into a rigid three-dimensional structure. Bioactive glass was first cleared by the FDA in Jan 1985 and has a history of safe and effective use in musculoskeletal surgery.
The flexibility of the CLM system enables optimization of mechanical and biological properties for specific applications yielding the following benefits:
• Predicable resorption
• High strength
• Variable porosity
• Interconnected pores
• Low cost to manufacture
More than 2,000 experiments and iterative animal testing have been completed in the development of the CLM process. In rabbit studies, CLM materials successfully demonstrated:
• Bone ingrowth throughout implant at eight weeks
• Equivalent performance compared to other osteostimulative bone graft materials
• Implant resorption ongoing at 24 weeks post-op.
The cost and performance characteristics of Bio2 Technologies’ CLM process provide many advantages over other bone grafting options.
Bio2 Technologies aggressively pursues patent protection of its CLM technology. Our patent portfolio includes:
• Seven issued U.S. patents
• Four issued China patents
• Two issued Japan patents
• Two issued Israel patents
• 15 pending U.S. patent applications
• 44 international filings in eight countries to secure exclusive rights worldwide